Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Azyan Telecom Signs Order With Kymeta to Bring First Flat Panel Terminal to LEO Market in Oman
Apple’s iPhone 15 Debut Includes Higher Price on Top Model
Peloton apologises after issues with Thanksgiving ride: ‘We let you down’
Calm Waters AI Achieves 97% Evaluation & Management Chart Accuracy as Audited by Mazars
Watch live: Meta showcases new AR and VR tech at annual Connect conference
Weave Named One of Utah’s Top Companies Championing Women
Masimo Announces FDA 510(k) Clearance of Radius VSM™
Miami’s Overflowing Septic Tanks and Trash Piles Test Appeal to Rich